IRONWOOD PHARMACEUTICALS INCIRWD
| Dec 31,
2011 | Dec 31,
2012 | Dec 31,
2013 | Dec 31,
2014 | Dec 31,
2015 | Dec 31,
2016 | Dec 31,
2017 | Dec 31,
2018 | Dec 31,
2019 | Dec 31,
2020 | Dec 31,
2021 | Dec 31,
2022 | Dec 31,
2023 |
|---|
| Collaborative arrangements revenue | - | - | - | - | - | - | - | 273 | 380 | 382 | 413 | 411 | 443 |
|---|
| Sale of active pharmaceutical ingredient | - | - | - | - | - | - | - | 70 | 49 | 8 | 1 | - | - |
|---|
| Total revenues | 66 | 150 | 23 | 76 | 150 | 274 | 298 | 347 | 428 | 390 | 414 | 411 | 443 |
|---|
| Cost of revenues | - | - | - | - | - | - | - | 33 | 24 | 3 | - | - | - |
|---|
| Research and development | 86 | 113 | 102 | 102 | 109 | 139 | 148 | 167 | 115 | 88 | 70 | 44 | 116 |
|---|
| Research and development | 86 | 113 | 102 | 102 | 109 | 139 | 148 | 167 | 115 | 88 | 70 | 44 | 116 |
|---|
| Selling, general and administrative | - | 93 | 123 | 118 | 125 | 173 | 233 | 241 | 172 | 140 | 111 | 116 | 158 |
|---|
| Selling, general and administrative | - | 93 | 123 | 118 | 125 | 173 | 233 | 241 | 172 | 140 | 111 | 116 | 158 |
|---|
| Restructuring expenses | - | - | - | - | - | - | - | - | - | - | -0 | - | 18 |
|---|
| Restructuring expenses | - | - | - | - | - | - | - | - | - | - | -0 | - | 18 |
|---|
| Acquired in-process research and development | - | - | - | - | - | - | - | - | - | - | - | - | 1,095 |
|---|
| Total costs and expenses | - | 223 | 275 | 246 | 252 | 326 | 376 | 586 | 308 | 247 | 181 | 160 | 1,388 |
|---|
| Income (loss) from operations | -66 | -73 | -252 | -169 | -102 | -52 | -77 | -239 | 120 | 143 | 232 | 250 | -945 |
|---|
| Interest expense and other financing costs | 0 | 0 | 21 | 21 | 31 | 39 | 36 | 38 | 37 | 29 | 31 | 8 | 22 |
|---|
| Investment Income, Net | - | - | 0 | 0 | 0 | 1 | 2 | 3 | 3 | 2 | 1 | 10 | 19 |
|---|
| Gain (loss) on derivatives | - | - | - | - | -10 | 8 | -3 | -9 | 3 | -6 | -1 | 0 | 0 |
|---|
| Other income | 1 | - | - | 1 | - | - | - | - | 1 | 0 | - | - | - |
|---|
| Other income (expense), net | 1 | 0 | -21 | -20 | -41 | -30 | -40 | -43 | -61 | -34 | -32 | 2 | -3 |
|---|
| Other income (expense), net | 1 | 0 | -21 | -20 | -41 | -30 | -40 | -43 | -61 | -34 | -32 | 2 | -3 |
|---|
| Income (loss) before income taxes | -65 | -73 | -273 | - | - | - | - | - | - | 109 | 201 | 252 | -948 |
|---|
| Income tax (expense) benefit | 0 | - | - | - | - | - | - | - | - | 3 | -328 | 77 | 83 |
|---|
| Net income (loss) attributable to Ironwood Pharmaceuticals, Inc. | -65 | -73 | - | - | - | - | -117 | -282 | 22 | 106 | 528 | 175 | -1,002 |
|---|
| Comprehensive income | - | - | - | - | - | - | - | - | - | 106 | 528 | 175 | - |
|---|
| Earnings Per Share, Basic | - | - | - | - | - | - | - | - | - | 0.67 | 3.26 | 1.13 | -6.45 |
|---|
| Earnings Per Share, Diluted | - | - | - | - | - | - | - | - | - | 0.66 | 3.21 | 0.96 | -6.45 |
|---|
| Collaborative arrangements revenue | - | - | - | - | - | - | - | 273 | 380 | 382 | 413 | 411 | 443 |
|---|
| Sale of active pharmaceutical ingredient | - | - | - | - | - | - | - | 70 | 49 | 8 | 1 | - | - |
|---|
| Total revenues | 66 | 150 | 23 | 76 | 150 | 274 | 298 | 347 | 428 | 390 | 414 | 411 | 443 |
|---|
| Cost of revenues | - | - | - | - | - | - | - | 33 | 24 | 3 | - | - | - |
|---|
| Research and development | 86 | 113 | 102 | 102 | 109 | 139 | 148 | 167 | 115 | 88 | 70 | 44 | 116 |
|---|
| Research and development | 86 | 113 | 102 | 102 | 109 | 139 | 148 | 167 | 115 | 88 | 70 | 44 | 116 |
|---|
| Selling, general and administrative | - | 93 | 123 | 118 | 125 | 173 | 233 | 241 | 172 | 140 | 111 | 116 | 158 |
|---|
| Selling, general and administrative | - | 93 | 123 | 118 | 125 | 173 | 233 | 241 | 172 | 140 | 111 | 116 | 158 |
|---|
| Restructuring expenses | - | - | - | - | - | - | - | - | - | - | -0 | - | 18 |
|---|
| Restructuring expenses | - | - | - | - | - | - | - | - | - | - | -0 | - | 18 |
|---|
| Acquired in-process research and development | - | - | - | - | - | - | - | - | - | - | - | - | 1,095 |
|---|
| Total costs and expenses | - | 223 | 275 | 246 | 252 | 326 | 376 | 586 | 308 | 247 | 181 | 160 | 1,388 |
|---|
| Income (loss) from operations | -66 | -73 | -252 | -169 | -102 | -52 | -77 | -239 | 120 | 143 | 232 | 250 | -945 |
|---|
| Interest expense and other financing costs | 0 | 0 | 21 | 21 | 31 | 39 | 36 | 38 | 37 | 29 | 31 | 8 | 22 |
|---|
| Investment Income, Net | - | - | 0 | 0 | 0 | 1 | 2 | 3 | 3 | 2 | 1 | 10 | 19 |
|---|
| Gain (loss) on derivatives | - | - | - | - | -10 | 8 | -3 | -9 | 3 | -6 | -1 | 0 | 0 |
|---|
| Other income | 1 | - | - | 1 | - | - | - | - | 1 | 0 | - | - | - |
|---|
| Other income (expense), net | 1 | 0 | -21 | -20 | -41 | -30 | -40 | -43 | -61 | -34 | -32 | 2 | -3 |
|---|
| Other income (expense), net | 1 | 0 | -21 | -20 | -41 | -30 | -40 | -43 | -61 | -34 | -32 | 2 | -3 |
|---|
| Income (loss) before income taxes | -65 | -73 | -273 | - | - | - | - | - | - | 109 | 201 | 252 | -948 |
|---|
| Income tax (expense) benefit | 0 | - | - | - | - | - | - | - | - | 3 | -328 | 77 | 83 |
|---|
| Net income (loss) | -65 | -73 | - | - | - | - | -117 | -282 | 22 | 106 | 528 | 175 | -1,032 |
|---|
| Net Income (Loss) Attributable to Noncontrolling Interest | - | - | - | - | - | - | - | - | - | - | - | - | -29 |
|---|
| Net income (loss) attributable to Ironwood Pharmaceuticals, Inc. | -65 | -73 | - | - | - | - | -117 | -282 | 22 | 106 | 528 | 175 | -1,002 |
|---|
| Earnings Per Share, Basic | - | - | - | - | - | - | - | - | - | 0.67 | 3.26 | 1.13 | -6.45 |
|---|
| Earnings Per Share, Diluted | - | - | - | - | - | - | - | - | - | 0.66 | 3.21 | 0.96 | -6.45 |
|---|